LB-102 in Phase 2 Data Shows Promise for Treating Acute

Описание: In a phase 2 randomized, double-blind trial, LB-102, a once-daily benzamide antipsychotic, significantly reduced PANSS scores in adults with acute schizophrenia. Check out the full interview with John M. Kane here: https://www.hcplive.com/view/phase-2-...